datetime,headline,summary,related,lang,source
2020-11-26 07:24:57-05:00,"Saudi, Abu Dhabi wealth funds team up on Egyptian drugmaker deal",Public Investment Fund and ADQ are weighing the purchase of Bausch Health’s Cairo-based drug unit.,BHC,en,Gulf Business
2020-11-25 08:37:14-05:00,"Dermatology Treatment Devices Market Is Expected To Reach US$ 8,800.07 Million In By 2027 With Cutera Inc.; Bausch Health Companies Inc.; Sciton, Inc.; Lumenis; Alma Lasers; Cynosure, Candela Corporation; Biofrontera Ag; Avita Medical; and PhotoMedex","The proposed Dermatology Treatment Devices Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes","BFRA,BHC",en,OpenPR
2020-11-24 07:00:00-05:00,Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction,"LAVAL, Quebec, Nov. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of two Phase 3 studies evaluating the…",BHC,en,PR Newswire
2020-11-23 02:51:45-05:00,"Medical Aesthetics Market : Expected to Deliver Dynamic Progression until 2027 | Major Players Allergan, Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd",DBMR has added a new report titled Medical Aesthetics Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from,BHC,en,OpenPR
2020-11-18 16:51:00-05:00,Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes,"Following Redemptions, Bausch Health Will Have No Note Maturities Until 2024 LAVAL, QC, Nov. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") announced today that it has priced and upsized its previously announced offering of $1.0…",BHC,en,PR Newswire
2020-11-17 14:00:00-05:00,Warren Buffett Just Made Huge Bets in This Surging Industry: It’s Time to Follow Him!,Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) stock is a great TSX stock to buy if you're like Warren Buffett and see a healthcare bull market. The post Warren Buffett Just Made Huge Bets in This Surging Industry: It’s Time to Follow Him! appeared first on The Motley Fool Canada .,BHC,en,The Motley Fool Canada
2020-11-16 07:00:00-05:00,Bausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY® And BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride,"LAVAL, Quebec, Nov. 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and Bausch + Lomb, its leading global eye health business, today announced the results of new investigational in vitro data showing that two benzalkonium chloride (BAK) preserved…",BHC,en,PR Newswire
2020-11-12 07:15:32-05:00,"Global Medical Aesthetics Market 2020-2026 Refreshing Trends || Major Giants – Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd., Cynosure","ew report published by Data Bridge Market Research which offers insights on the “Global Medical Aesthetics Market”. The report delivers a comprehensive overview of the crucial elements of the market and elements such as drivers, restraints, current trends of the",BHC,en,OpenPR
2020-11-11 07:00:00-05:00,Salix To Present Data At AASLD's The Liver Meeting Digital Experience,"LAVAL, QC, Nov. 11, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and its gastroenterology (GI) business, Salix Pharmaceuticals, (""Salix""), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of…",BHC,en,PR Newswire
2020-11-10 07:00:00-05:00,Bausch Health Announces Participation In Upcoming Investor Conferences,"LAVAL, Quebec, Nov. 10, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") today announced that the Company will participate in two investor conferences. Joseph C. Papa, chairman and chief executive officer, Sam Eldessouky, senior vice…",BHC,en,PR Newswire
2020-11-10 06:38:14-05:00,Bausch Health Business on the Mend,"When Bausch Health (TSX:BHC) posted quarterly results on Nov. 3, the stock did not move by much end ended going nowhere. BHC posted a non-GAAP EPS of $1.31. Revenue fell 3.2% Y/Y to $2.14 billion. BHC stock did not react positively to the results …",BHC,en,Baystreet Canada
2020-11-09 10:55:34-05:00,"Hyaluronidase Market Expand with Huge Growth By 2020-2027 | Top Companies like PrimaPharm, Bausch, Amphastar, Halozyme, CooperSurgical Fertility, Shreya Life Sciences, Sun, CBC Pharma","The report on Global Hyaluronidase Market 2020 includes a study of annual and financial reports of top players, Market Share and Market Size. This research report offers in-depth study of Key Players, Product and Regional Analysis over the forecast period",BHC,en,OpenPR
2020-11-09 02:06:11-05:00,"Dry Eye Products Market Will Going to Be Worth US$ 9,141.01 million by 2027; Industry Bigwigs Such as Novartis, OASIS Medical, AbbVie, Bausch Health Companies, Johnson and Johnson Services","The Insight Partners has published a new report titled, Dry Eye Products Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2027’. According to our latest study the market was valued at US$ 6,385.14 million in 2019 and",BHC,en,OpenPR
2020-11-06 09:04:01-05:00,"Global Medical Aesthetics Market Share By 2026:Allergan, Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd.",Global Medical Aesthetics Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the business.,BHC,en,OpenPR
2020-11-06 05:24:13-05:00,"Parkinson's Disease Treatment Market 2020: Top Key Players Are Teva (Israel), Acadia (US), Impax Laboratories (US), GSK (UK), Novartis AG (Switzerland), UCB (Belgium), Valeant Pharmaceuticals (Canada), Boehringer Ingelheim (Germany), Sun Pharma (India), L","Industry Overview: Updated research report on Parkinson's Disease Treatment Market by ‘Market Growth Insight’ delivers pivotal information on the market including drivers, restraints, challenges, and opportunities. The Parkinson's Disease Treatment report is useful to business owners, manufacturers, distributors, suppliers, marketing personnel,",BHC,en,OpenPR
2020-11-05 13:55:19-05:00,"DiGeorge Syndrome Drug Market 2020 Share Analysis By Aevi Genomic Medicine, Inc, Bausch Health, Natera, Inc, Roche Sequencing, Enzyvant, Progenity, Inc., Boehringer Ingelheim International GmbH",DiGeorge syndrome drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Growing incidence of DiGeorge syndrome’s population and the development of newer therapies and treatment are the key factors for market growth. Global DiGeorge,BHC,en,OpenPR
2020-11-04 08:16:29-05:00,"Drug Delivery Systems Market Account To US$ 2,302.2 Bn By 2027 With Key Players BD, Novo Nordisk A/S, 3M, Boston Scientific Corporation, Bausch Health Companies, Baxter International, Boehringer Ingelheim, Novartis AG, GlaxoSmithKline plc., and Johnson &","A new research document with title Global Drug Delivery Systems Market Report covering detailed analysis, Competitive landscape, forecast and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions like North America, Europe and",BHC,en,OpenPR
2020-11-04 03:02:57-05:00,"Ophthalmic Drugs Market With Top Players like Aerie Pharmaceuticals, Allergan, Bausch Health Companies, Santen Pharmaceutical Co., Ltd. Regeneron, Novartis AG, Bayer AG, Otsuka Pharmaceutical Co., Ltd. F. Hoffmann-La Roche Ltd, Pfizer","Ophthalmic drugs are sterile preparations designed to treat several eye disorders. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. An off-the-shelf report on Ophthalmic Drugs Market which has been compiled after",BHC,en,OpenPR
2020-11-03 16:30:48-05:00,Bausch Health Companies (TSX:BHC) Stock: A Top Canadian Healthcare Stock to Buy Today,Bausch Health stock is a stock to buy today for its defensive healthcare business and its strong long-term growth profile. The post Bausch Health Companies (TSX:BHC) Stock: A Top Canadian Healthcare Stock to Buy Today appeared first on The Motley Fool Canada .,BHC,en,The Motley Fool Canada
2020-11-03 11:48:26-05:00,Bausch Health Companies Inc. (BHC) Q3 2020 Earnings Call Transcript,"Bausch Health Companies Inc. (NYSE: BHC) Q3 2020 earnings call dated Nov. 03, 2020 Presentation: Operator Good morning, and welcome to the Bausch Health Third Quarter 2020 Earnings Call. [Operator […]",BHC,en,AlphaStreet
2020-11-03 06:59:00-05:00,Bausch Health Companies Inc. Announces Third-Quarter 2020 Results,"LAVAL, Quebec, Nov. 3, 2020 /PRNewswire/ -- Third-Quarter 2020 Financial Results Revenues of $2.138 Billion GAAP Net Income of $71 Million Adjusted EBITDA (non-GAAP) 1 of $948 Million GAAP Cash Generated from Operations of $256 Million Reaffirmed 2020 Full-Year Revenue and Adjusted EBITDA…",BHC,en,PR Newswire
2020-10-30 01:16:00-05:00,Bausch Health's rifaximin an Orphan Drug in U.S. for sickle cell disease (NYSE:BHC),"The FDA grants Orphan Drug Designation to Bausch Health Companies (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals' rifaximin for the tr",BHC,en,Seeking Alpha
2020-10-29 15:05:00-05:00,Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease,"LAVAL, QC, Oct. 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and its gastroenterology business, Salix Pharmaceuticals (""Salix""), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of…",BHC,en,PR Newswire
2020-10-27 07:29:46-05:00,"Specialty Generics Market Worth Observing Growth by 2026: Teva Pharmaceutical, Valeant Pharmaceuticals International, Mylan NV","A new business intelligence report released by HTF MI with title ""Global Specialty Generics Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)"" is designed covering micro level of",BHC,en,OpenPR
2020-10-27 06:00:00-05:00,"Global Chemical Peel Market- Featuring Allergan Plc, Bausch Health Companies Inc., Colgate-Palmolive Co., Among Others | Technavio",LONDON--(BUSINESS WIRE)-- #ChemicalPeelMarket--The Global Chemical Peel Market will grow by $ 62.78 million during 2020-2024,BHC,en,Business Wire
2020-10-26 05:58:00-05:00,Ortho Dermatologics To Present New Analyses At The Virtual Fall Clinical Dermatology Conference,"LAVAL, QC, Oct. 26, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest dermatology health care businesses in the world, today announced the presentation of nine posters during the virtual Fall Clinical…",BHC,en,PR Newswire
2020-10-23 09:17:32-05:00,Piper Sandler Weighs in on Bausch Health Companies Inc’s Q4 2020 Earnings (NYSE:BHC),"Bausch Health Companies Inc (NYSE:BHC) – Piper Sandler reduced their Q4 2020 earnings estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Wednesday, October 21st. Piper Sandler analyst D. Amsellem now forecasts that the company will post earnings per share of $1.22 for the quarter, down from […]",BHC,en,Transcript Daily
2020-10-23 00:50:42-05:00,Stock Traders Purchase High Volume of Call Options on Bausch Health Companies (NYSE:BHC),"Bausch Health Companies Inc (NYSE:BHC) was the target of unusually large options trading on Wednesday. Stock investors bought 43,703 call options on the company. This represents an increase of approximately 110% compared to the typical volume of 20,810 call options. BHC has been the subject of a number of analyst reports. Bank of America upgraded […]",BHC,en,Zolmax News
2020-10-22 06:00:00-05:00,Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting,"Eleven Scientific Posters to be Featured LAVAL, QC, Oct. 22, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and its gastroenterology (GI) business, Salix Pharmaceuticals, (""Salix""), one of the largest specialty pharmaceutical companies in the world…",BHC,en,PR Newswire
2020-10-22 02:50:41-05:00,Short Interest in Bausch Health Companies Inc (NYSE:BHC) Grows By 17.0%,"Bausch Health Companies Inc (NYSE:BHC) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 19,300,000 shares, an increase of 17.0% from the September 15th total of 16,500,000 shares. Based on an average daily volume of 4,470,000 shares, the short-interest ratio is presently 4.3 […]",BHC,en,Zolmax News
2020-10-21 14:20:41-05:00,"Skin Tightening Market 2020 Indepth Study Including COVID 19 Update with of Top Key Players Profile: Merz Pharma, Bausch Health Companies Inc, Hologic, Inc, Cutera, Venus Concept, ALLERGAN","Data Bridge Market Research has recently added a concise research on the Skin Tightening Market - Industry Trends and Forecast to 2026. Skin Tightening Market research report has been prepared with a nice combination of industry insight, smart solutions, practical",BHC,en,OpenPR
2020-10-20 09:15:10-05:00,"Expecting Astounding Growth in Liposuction Devices Market 2020-2027 | Alma Lasers, Cynosure, Erchonia, Genesis Biosystems, Valeant Pharmaceuticals","A professional survey done by HealthCare Intelligence Markets has formulated a report titled “Liposuction Devices Market”, which instils a crisp idea of the influential aspects affecting the growth of the market. It gives the new entrants a clear idea of",BHC,en,OpenPR
2020-10-20 08:20:29-05:00,"Medical Implanting Material Market Worth Observing Growth | Ophtec, Boston Scientific, Bausch + Lomb, Lenstec, Johnson & Johnson, Medtronic","The most advanced study released by AMR on the Medical Implanting Material market comprising key market segments such as Type, Application, Sales, Growth, Comprises details of companies manufacturing field, production volume, capacities, value chain, product specifications, raw material sourcing strategies,",BHC,en,OpenPR
2020-10-19 10:28:26-05:00,"DBMR Updates : Physician Dispensed Cosmeceuticals Market Forecast And Analysis As Corona Virus Outbreak Disturbs Investment Plans, Leading Players are ALLERGAN, Jan Marini Skin Research, Johnson & Johnson, Clarisonic, Unilever, Bausch Health","Physician Dispensed Cosmeceuticals Market report has been formulated by keeping in mind all the vital aspects of the market research that simply brings market landscape into focus. CAGR value fluctuation percentage for market, during the forecast period of 2020-2026 can",BHC,en,OpenPR
2020-10-19 09:45:16-05:00,"Cannabis Pharmaceuticals Market Significance, Overview, and Worldwide Outlook By Abbvie Inc. , Insys Therapeutics, Inc. , GW Pharmaceuticals , Valeant Pharmaceuticals , Tilray , Cardiol Therapeutics , Cure Pharmaceutical , Zynerba Pharmaceuticals, Inc.","The proposed Cannabis Pharmaceuticals Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed",BHC,en,OpenPR
2020-10-19 07:57:49-05:00,"Eczema Therapeutics Market 2020-28 advance research lead towards gigantic hike| Bausch Health Companies, Bayer AG, Eli Lilly, Encore Dermatology, LEO Pharma AS, Mylan NV, Pfizer, and Sanofi",Eczema is a term for a group of conditions that make your skin inflamed or irritated. The most common type is atopic dermatitis or atopic eczema. “Atopic” refers to a person's tendency to get allergic conditions such as asthma and,BHC,en,OpenPR
2020-10-19 01:59:12-05:00,ADQ eyes acquiring Bausch's Egyptian drug unit,"UAE - Mubasher: ADQ, an Abu Dhabi-based holding company, is considering a potential acquisition of Bausch Health Companies' Egyptian drug unit, known as Amoun Pharmaceutical Co, sources told Bloomberg. Sources noted that ADQ is studying the …",BHC,en,Mubasher Info
2020-10-16 08:59:22-05:00,"Postpartum Depression Market Growth Factors, Trends, and Top Companies Analysis for Business Development| GlaxoSmithKline Plc., Alvogen, Bausch Health Companies Inc., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd",Postpartum depression market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of mood,BHC,en,OpenPR
2020-10-16 04:45:19-05:00,"Global Medical Aesthetics Market (COVID - 19 Updates) 2020-2027 Research Report | Know The Growth Factors and Future Scope || Allergan, Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd",A DBMR team makes use of simple language and easy to understand statistical images to provide thorough information and in-depth data on the industry and Global Medical Aesthetics Market. The company profiles of all the key players and brands that,BHC,en,OpenPR
2020-10-16 02:50:49-05:00,"Irritable Bowel Syndrome Treatment Market Rising Trends Forecast to 2027 | Leading Players Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International","Latest released the research study on Global Irritable Bowel Syndrome Treatment Market, offers a detailed overview of the factors influencing the global business scope. Irritable Bowel Syndrome Treatment Market research report shows the latest market insights, current situation analysis with",BHC,en,OpenPR
2020-10-15 06:00:00-05:00,Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens,"Second Exclusive License Strengthens Bausch + Lomb's Global Research Focus on Myopia SYDNEY and LAVAL, QC, Oct. 15, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian…",BHC,en,PR Newswire
2020-10-13 15:00:00-05:00,"Worldwide Topical Drug Delivery Industry to 2025 - Featuring Bausch Health, Hisamitsu Pharmaceutical & Nestle Among Others","DUBLIN, Oct. 13, 2020 /PRNewswire/ -- The ""Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting (Homecare, Hospital, Burn Center) COVID-19 Impact - Global Forecast…",BHC,en,PR Newswire
2020-10-13 02:46:52-05:00,"Global Cutaneous Horn Treatment Market 2020 Industry Outlook - F. Hoffmann-La Roche AG, Bausch Health Companies Inc.","The newly added research report entitled Global Cutaneous Horn Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 carries-out a multi-dimensional assessment gauging into factors such as vendor landscape with references of competitors, their market positions as",BHC,en,OpenPR
2020-10-12 08:26:53-05:00,"Topical Corticosteroids Market Business Strategies, Growth Rate, Size, Share and Leading Players- GlaxoSmithKline plc, Merck Sharp & Dohme Corp., LEO, Almirall, S.A, Bausch Health","A persuasive Topical Corticosteroids Market report identifies, estimates, and analyses the emerging trends along with major drivers, restraints, challenges and opportunities in the market. The research and analysis carried out in this report helps clients to predict investment in an",BHC,en,OpenPR
2020-10-12 06:00:00-05:00,Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12,"LAVAL, QC and NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: EYEN) (""Eyenovia""), a clinical stage ophthalmic biopharmaceutical company developing a…",BHC,en,PR Newswire
2020-10-09 13:30:00-05:00,"Insights on the Optometry Global Market to 2027 - Featuring Allergan, Bausch Health Companies & CooperVision Among Others","DUBLIN, Oct. 9, 2020 /PRNewswire/ -- The ""Optometry - Global Market Trajectory & Analytics"" report has been added to ResearchAndMarkets.com's offering. The publisher brings years of research experience to the 8th edition of this report. The 135-page report presents concise insights into…",BHC,en,PR Newswire
2020-10-09 08:38:55-05:00,"Eyedrops Market to See Huge Growth by 2026 | Santen, Bausch, Allergan, ZSM","A study published on COVID-19 Outbreak-Global Eyedrops Market, includes exploratory survey, qualitative commentary on changing market dynamics with market sizing and estimates for 18+ Global Countries, business segments and applications. The identification of hot and emerging players is completed by",BHC,en,OpenPR
2020-10-09 08:32:13-05:00,"Medical Aesthetics Market Future Scope, Business Opportunities, Demand, Growth and Leading Manufacturers - Allergan, Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd., Cynosure","Medical Aesthetics Market report gives details about historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry in this market research report. The Medical",BHC,en,OpenPR
2020-10-09 06:53:09-05:00,Why Bausch Health Companies Stock (TSX:BHC) Soared 12% Yesterday,Bausch Health stock is one that we at Motley Fool recognize for its long-term potential. Here's why yesterday's 12% increase is just the beginning. The post Why Bausch Health Companies Stock (TSX:BHC) Soared 12% Yesterday appeared first on The Motley Fool Canada .,BHC,en,The Motley Fool Canada
2020-10-08 11:03:10-05:00,"COVID-19 UPDATE: Global Medical Aesthetics Market Likely to Experience a Tremendous Growth in Near Future|| Allergan, Bausch Health Companies Inc., Lumenis, Shanghai Fosun Pharmaceutical Group Co. Ltd",Data Bridge Market Research has recently added a concise research on the Global Medical Aesthetics Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by,BHC,en,OpenPR
2020-10-08 09:57:27-05:00,"FXNEWS24 |BUZZ-U.S. STOCKS ON THE MOVE-Medtronic, Carnival, JetBlue Airways, Bausch Health, Gilead, Cytokinetics | UK Forex Reviews","BUZZ-U.S. STOCKS ON THE MOVE-Medtronic, Carnival, JetBlue Airways, Bausch Health, Gilead, Cytokinetics | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News",BHC,en,FXNews24
2020-10-08 07:00:00-05:00,Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020,"Scientific Posters Span Across Salix's Gastroenterology Portfolio BRIDGEWATER, N.J., Oct. 8, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and its gastroenterology business, Salix Pharmaceuticals, (""Salix""), one of the largest specialty pharmaceutical…",BHC,en,PR Newswire
2020-10-08 06:00:00-05:00,Bausch Health Companies Inc. Provides Preliminary Update On Third-Quarter 2020 Financial Results And Business Recovery,"Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") today provided a preliminary update on its third-quarter 2020 financial results and the pace of its business recovery from the COVID-19 pandemic.",BHC,en,Yahoo Finance
2020-10-07 14:01:31-05:00,"Botulism Treatment Market Sees a Faster Rebound in the Era of COVID-19 | Industry Size, Share, Growth Factors, Development Strategy, Top Leaders-XOMA, Microbiotix, Valeant Pharmaceuticals, Morphotek, Medytox Solutions, Merz Pharma","The Botulism Treatment Market report contains the list of leading competitors, strategic industry analysis and the insights of key factors influencing the industry. To prosper in this competitive market place, businesses are highly benefited if they adopt innovative solutions such as",BHC,en,OpenPR
2020-10-07 08:23:14-05:00,OTC Drug and Dietary Supplement Market Witness Huge Growth by 2027: Key Players GlaxoSmithKline; Sanofi; Johnson and Johnson Services; Abbott; AbbVie; Bausch Health Companies; Bayer AG; Procter & Gamble; Novartis AG; Reckitt Benckiser Group,"A new research document with title Global OTC Drug and Dietary Supplement Market Report covering detailed analysis, Competitive landscape, forecast and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions like North America,",BHC,en,OpenPR
2020-10-06 06:00:00-05:00,Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse™ Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting,"LAVAL, QC, Oct. 6, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), today announced that three poster presentations will feature the company's new silicone hydrogel (SiHy) daily disposable contact…",BHC,en,PR Newswire
2020-10-05 06:52:53-05:00,"Sinus Dilation Devices Market Competitive Landscape By Stryker, Sklar Surgical Instruments, BAUSCH & LOMB INCORPORATED, Medical Devices Business Services, Inc., Medtronic","Sinus Dilation Devices Market By Product (Sinus Stents/Implants, Balloon Sinuplasty Systems, Endoscope, FEES Instruments Set, Handheld Instruments), Procedure (Standalone Sinus Dilation, Hybrid Sinus Dilation), Patient Group (Pediatric, Adults), End User (Hospitals, ENT Clinics/In Office, ASCs, Others), Country (U.S., Canada, Mexico,",BHC,en,OpenPR
2020-10-01 09:00:00-05:00,"Eyewear Market to Reach USD 57.69 bn by 2024, Bausch Health Companies Inc and Carl Zeiss AG Emerge as Key Contributors to Growth | Technavio",LONDON--(BUSINESS WIRE)-- #EyewearMarket--The Global Eyewear Market will grow by USD 57.69 bn during 2020-2024,BHC,en,Business Wire
2020-10-01 06:00:00-05:00,Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List,"LUMIFY® Recognized in the ""Superstar"" Category for Exceptional Sales and Growth LAVAL, QC, Oct. 1, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), today announced that BASES, a Nielsen Global…",BHC,en,PR Newswire
2020-10-01 05:02:59-05:00,"Ophthalmic Devices Market Checkout the Unexpected Future 2027 | Key Players - Bausch + Lomb, Johnson & Johnson, Alcon, Topcon, Carl Zeiss Meditec","Global Ophthalmic Devices Market has been brewing up and influencing the international economy with respect to revenue, growth rate, sale, market share, and size. The Global Ophthalmic Devices Market research report provides a rational explanation to the reader to understand",BHC,en,OpenPR
2020-10-01 03:37:47-05:00,Logistics visit: Bettel and Bausch drop in on CFL hub in Bettembourg,"Prime Minister Xavier Bettel and Deputy Prime Minister François Bausch visited the CFL multimodal and CFL cargo intermodal site which, as one of the main players in logistics, provides national and international rail freight transport.",BHC,en,RTL Today
2020-09-30 14:18:02-05:00,"Vaginitis Therapeutics Market Shares and SWOT Analysis by Lupin, Pfizer Inc, Sanofi, Teva Pharmaceutical Industries Ltd, Bausch Health, DARÉ BIOSCIENCE, INC","Vaginitis Therapeutics Market By Types (Bacterial Vaginosis, Trichomoniasis, Vulvovaginal Candidiasis and Others), Drug Class (Anti-fungal, Anti-bacterial, Hormone and Others), Medication Type (Over-The-Counter (OTC), Prescription (Rx)), Route of Administration (Oral, Topical), End- Users (Hospitals, Specialized Gynecology Centers and Others), Distribution Channel",BHC,en,OpenPR
2020-09-30 06:19:05-05:00,"Tinea Pedis Treatment Market Anticipated to Grow Rapidly During 2027 - Bausch Health, GlaxoSmithKline, Novartis AG, Aqua Pharmaceuticals, Bayer AG and Perrigo Company",A new market report by The Insight Partners on the Tinea Pedis Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis,BHC,en,OpenPR
2020-09-29 14:40:34-05:00,"Andrew Left Talks Inovio, Fluidigm And His 'Biggest Mistake As A Short Seller'","Citron Research founder and activist short seller Andrew Left discussed his latest ideas during an appearance on Benzinga’s PreMarket Prep show Tuesday morning. Left has gained notoriety over the years for successfully betting against Bausch Health Companies Inc (NYSE: BHC ) (formerly Valeant Pharmaceuticals) and a number of fraudulent Chinese stocks, but has also come out positive on a number of stocks he believes are true winners. Short Ideas: One of Left’s current short positions is COVID-19 vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO ), which Left calls “Pinocchio Pharmaceuticals.” “They were pretty much told by the FDA they can not start Phase 2, so they’re stuck in Phase 1. Now we’re 30 years [with] no product,” Left said. “I don’t know why it’s worth anything more than cash…They said they developed a vaccine in three hours...yet it’s going to take them a month to answer the FDA about this vaccine. Short-term it should definitely trade at $6 or $7.” Left also recently compared Chinese education stock GSX Techedu Inc (NYSE: GSX ) to fraud Luckin Coffee Inc - ADR (OTC: LKNCY ). “If it’s not a fraud, they’re a better company than Snowflake than Google, than Facebook ever was.",BHC,en,Benzinga
2020-09-28 03:56:26-05:00,Bausch Scores FDA Approval For Preservative Free Allergy Eyedrop,Bausch Health Companies and Eton Pharmaceuticals together announced on Friday that the U.S. The post Bausch Scores FDA Approval For Preservative Free Allergy Eyedrop appeared first on Smarter Analyst .,BHC,en,Smarter Analyst
2020-09-25 07:00:00-05:00,"FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%","LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA)…",BHC,en,PR Newswire
2020-09-20 20:16:35-05:00,"The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix","Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here're the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual Sickle Cell Disease Research and Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting (virtual event): Sept. 23-25 PDUFA Dates The FDA could announce its decision on Bausch Health Companies Inc's (NYSE: BHC ) NDA for EM-100, …",BHC,en,Benzinga
2020-09-17 19:03:07-05:00,Bausch Health Companies Inc. (BHC) Management Presents at Morgan Stanley Global Healthcare Conference Call Transcript,"Bausch Health Companies Inc. (NYSE:BHC) Morgan Stanley Global Healthcare Conference September 16, 2020 13:15 ET Corporate Participants Joe Papa - Chairman and Chief Executive Officer Paul Herendeen - Chief Financial Officer Conference Call Participants Dave Risinger - Morgan Stanley Presentation Dave Risinger Great.",BHC,en,Seeking Alpha
2020-09-17 18:18:49-05:00,Bausch Health (BHC) Presents At Morgan Stanley 18th Annual Global Healthcare Conference - Slideshow (NYSE:BHC),The following slide deck was published by Bausch Health Companies Inc. in conjunction with this event..,BHC,en,Seeking Alpha
2020-09-16 09:30:00-05:00,"Global Eyewear Market- Featuring Bausch Health Companies Inc, Carl Zeiss AG, and De Rigo Vision Spa Among Others",LONDON--(BUSINESS WIRE)-- #EyewearMarket--The Global Eyewear Market will grow by USD 57.69 bn during 2020-2024,BHC,en,Business Wire
2020-09-16 06:00:00-05:00,Bausch Health Provides Company Update At 18th Annual Morgan Stanley Global Healthcare Conference,"LAVAL, Quebec, Sept. 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") today announced it has published a presentation that Joseph C. Papa, chairman and CEO, and Paul S. Herendeen, executive vice president and chief financial officer,…",BHC,en,PR Newswire
2020-09-13 08:49:45-05:00,"The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference","Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market. The week also witnessed a flurry of news flow on the coronavirus vaccine front. Even as nine vaccine makers released a pledge to put safety first, AstraZeneca plc (NYSE: AZN ) was forced to voluntarily stall the late-stage study of its coronavirus vaccine, citing an unidentified illness in one of the trial participants. Clinical trials were allowed to resume on Sept. 12. Still, clinical trial readouts led to wild swings in some stocks. Here are the key catalysts for the unfolding week: Conferences: The International Parkinson and Movement Disorder Society, or MDS, Virtual Congress 2020: Sept. 12–16. H.C. Wainwright Virtual Healthcare Conference: Sept. 14-16 2nd RAS- Targeted Drug Development Summit 2020: Sept. 14-16 18th Annual Morgan Stanley Healthcare Conference: Sept. 14-18 2020 Cantor Global Virtual Healthcare Conference: Sept. 15-17 European Society for Medical Oncology, or ESMO, Virtual Congress 2020: Sept. 14-21 PDUFA Dates The FDA is set to rule on Bausch Health Companies Inc.'s (NYSE: BHC ) NDA for EM-100, a ketotifen preservative-free ophthalmic solution that is being evaluated for allergic conjunctivitis.",BHC,en,Benzinga
2020-09-10 06:00:00-05:00,Bausch Foundation Releases Inaugural Activity Report,"LAVAL, Quebec, Sept. 10, 2020 /PRNewswire/ -- The Bausch Foundation (""Foundation""), which oversees and directs the charitable giving efforts of Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), today released its Inaugural Activity Report, which highlights the efforts of the…",BHC,en,PR Newswire
2020-09-09 06:00:00-05:00,Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference,"LAVAL, QC, Sept. 9, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and CEO; Sam Eldessouky, senior vice president and corporate controller; and Arthur J. Shannon, senior vice president and head of Investor Relations and…",BHC,en,PR Newswire
2020-09-01 17:05:07-05:00,Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates,"August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Notable among the candidates that received the thumbs down were rheumatoid arthritis investigational therapy filgotinib sponsored by Gilead Sciences, Inc. (NASDAQ: GILD ) and BioMarin Pharmaceutical Inc.'s (NASDAQ: BMRN ) investigational gene therapy for hemophilia A. That said, the month saw approvals of eight new molecular entities, taking the total for the year to 38. Here are the key PDUFA dates scheduled for September. Bristol-Myers Squibb Awaits Nod For Blood Cancer Maintenance Therapy Company: Bristol-Myers Squibb Co's (NYSE: BMY ) Type of Application: NDA Candidate: CC-486 Indication: Acute myeloid leukemia Date: Aug. 3 CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia, who achieved complete remission or complete remission with incomplete blood count recovery.",BHC,en,Benzinga
2020-08-31 07:23:00-05:00,"Bausch + Lomb India urges consumers to ‘Live Better, Live Now’ in their new campaign",The digital campaign encourages people look at the positive lifestyle changes that have come along the last few months,BHC,en,The Financial Express
2020-08-31 06:00:00-05:00,Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations,"LAVAL, QC, Aug. 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") today announced it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations. Bausch Health will redeem…",BHC,en,PR Newswire
2020-08-27 05:22:08-05:00,Dr Reddy's launches Wilson's disease and cystinuria treatment capsules in US,"New Delhi: Pharma major Dr Reddy's Laboratories on Thursday said it has launched generic Penicillamine capsules, used for treatment of Wilson's disease and cystinuria, in the US market. The company announced the launch of Penicillamine capsules USP in the strength of 250 mg after it was approved by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE. The product is a generic version of Bausch Health Companies Inc's Cuprimine capsules in the same strength, it added. According to IQVIA Health data, the Cuprimine brand and generic market had US sales of approximately USD 80 million MAT for the most recent twelve months ending in June 2020, Dr Reddy's said. The capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Shares of Dr Reddy's Laboratories on Thursday closed 0.20 per cent lower at Rs 4,429.",BHC,en,Economic Times India
2020-08-25 05:46:47-05:00,Why Teva and Bausch Health Are Under-performing,"Teva (NYSE:TEVA) continues to trade at a discount because of its Cephalon unit. The opioid crisis is still a headwind hurting the stock. On Aug. 18, New York Governor Andrew Cuomo announced the DFS (Department of Financial Services) was suing Teva …",BHC,en,Baystreet Canada
2020-08-20 10:40:00-05:00,Pete Najarian Sees Unusual Activity In Merck And Bausch Health,"On CNBC's ""Fast Money Halftime Report,"" Pete Najarian said options traders were buying the August $87 calls in Merck & Co., Inc. …",BHC,en,Benzinga
2020-08-17 06:00:00-05:00,Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (SiHy) Daily Disposable Contact Lenses,"Next Generation Material Infused with Proprietary ProBalance Technology™ to Help Maintain Ocular Surface Homeostasis and Help Reduce Contact Lens Dryness, Which Affects More Than Half of Lens Wearers in the United States LAVAL, Quebec, Aug. 17, 2020 /PRNewswire/ -- Bausch + Lomb, a…",BHC,en,PR Newswire
2020-08-11 06:00:00-05:00,Health Canada Approves BAUSCH + LOMB ULTRA ONE DAY® Silicone Hydrogel Daily Disposable Contact Lenses,"LAVAL, QC, Aug. 11, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), today announced that it has received approval from Health Canada for the sale of BAUSCH + LOMB ULTRA® ONE DAY daily disposable…",BHC,en,PR Newswire
2020-08-09 08:05:25-05:00,"The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings","Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.",BHC,en,Benzinga
2020-08-07 18:00:00-05:00,"United States Acne and Rosacea Industry Insights 2020-2024 - Leading Players are Allergan, Bausch Health Companies, Leo Pharma, Sol Gel Technologies, Foamix Pharmaceuticals and Galderma","DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The ""US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)"" report has been added to ResearchAndMarkets.com's offering. The US acne market is expected to reach US$4.49 billion in 2024, recording growth at a CAGR of 4.12% during the period…",BHC,en,PR Newswire
2020-08-07 08:35:00-05:00,Analyzing Bausch Health's Unusual Options Activity,"On Friday, shares of Bausch Health Cos (NYSE: BHC) saw unusual options activity. After the option alert, the stock price moved down to $18.14. Sentiment: …",BHC,en,Benzinga
2020-08-06 19:00:00-05:00,Ophthalmic Lens Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increasing Prevalence of Refractive Errors to boost the Market Growth | Technavio,"Technavio has been monitoring the ophthalmic lens market and it is poised to grow by USD 3.21 billion during 2020-2024, progressing at a CAGR of over 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005720/en/ Technavio has announced its latest market research report titled Global Ophthalmic Lens Market 2020-2024 (Graphic: Business Wire) Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio's in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.",BHC,en,Benzinga
2020-08-06 15:24:47-05:00,"OraSure, Becton, Dickinson fall; Bausch, Vista Outdoor rise","Stocks that moved heavily or traded substantially on Thursday: OraSure, Becton, Dickinson fall; Bausch, Vista Outdoor rise",BHC,en,ABC News
2020-08-06 11:50:47-05:00,Why Bausch Health Stock (TSX:BHC) Is Rallying Almost 8%,"Despite the coronavirus pandemic, Bausch Health Companies stock continues rallying as the company spins off of its eye heath business. The post Why Bausch Health Stock (TSX:BHC) Is Rallying Almost 8% appeared first on The Motley Fool Canada .",BHC,en,The Motley Fool Canada
2020-08-06 10:39:52-05:00,"Jim Cramer: I Like Bausch, But Bristol-Myers Is Better",Jim Cramer weighs in on Bausch and its pan to spin off its eye-care division.,BHC,en,The Street
2020-08-06 09:33:36-05:00,Bausch Health To Spin Off Eye Care Business; Shares Surge 18%,"Shares in Bausch Health Companies spiked 18% as the Canadian drugmaker announced a plan to spin off its eye health care business, Bausch … The post Bausch Health To Spin Off Eye Care Business; Shares Surge 18% appeared first on Smarter Analyst .",BHC,en,Smarter Analyst
2020-08-06 09:15:26-05:00,"CANADA STOCKS-TSX scales 5-month high on Bausch Health, oil surge","Canada's main stock index scaled a five-month high on Thursday as a surge in shares of drugmaker Bausch Health and higher oil prices outweighed disappointment over earnings, including Bombardier's surprise quarterly loss.",BHC,en,Reuters
2020-08-06 06:41:20-05:00,Bausch Health Shares Soar On Baush & Lomb Eye Care Spin-Off Plans,Bausch Health shares surged higher Thursday after the company said it plans to spin-off is Bausch & Lomb eyecare division into a separate business.,BHC,en,The Street
2020-08-06 06:22:10-05:00,"Stocks making the biggest moves in the premarket: Hilton, Restaurant Brands, Bausch Health & more","The stocks making the biggest moves in premarket trading include Hilton, Restaurant Brands, Bausch Health, and more.",BHC,en,CNBC
2020-08-06 05:41:10-05:00,Bausch Health shares soar 23% premarket on report to spin off eye-care business,"Bausch Health Cos. shares undefined soared 23% in premarket trade Thursday, after a Wall Street Journal report that the company is planning to spin off its…",BHC,en,MarketWatch
2020-08-06 05:30:00-05:00,Bausch Health to Spin Off Eye-Care Business,"Bausch Health plans to spin off its faster-growing eye-care business from its core pharmaceutical operations, breaking apart a company previous management had built through such acquisitions, according to people familiar with the matter.",BHC,en,The Wall Street Journal
2020-08-06 04:28:26-05:00,"Earnings Scheduled For August 6, 2020","Companies Reporting Before The Bell ViacomCBS Inc. (NASDAQ: VIAC ) is projected to report quarterly earnings at $0.93 per share on revenue of $6.17 billion. Cardinal Health, Inc. (NYSE: CAH ) is estimated to report quarterly earnings at $0.92 per share on revenue of $36.88 billion. Bristol-Myers Squibb Company (NYSE: BMY ) is expected to report quarterly earnings at $1.48 per share on revenue of $9.97 billion. Becton, Dickinson and Company (NYSE: BDX ) is projected to report quarterly earnings at $2.04 per share on revenue of $3.94 billion. Ball Corporation (NYSE: BLL ) is estimated to report quarterly earnings at $0.56 per share on revenue of $2.86 billion. Sealed Air Corporation (NYSE: SEE ) is expected to report quarterly earnings at $0.57 per share on revenue of $1.09 billion. American Electric Power Company, Inc. (NYSE: AEP ) is projected to report quarterly earnings at $1.06 per share on revenue of $3.87 billion. Huntington Ingalls Industries, Inc. (NYSE: HII ) is expected to report quarterly earnings at $4.17 per share on revenue of $2.14 billion.",BHC,en,Benzinga
2020-08-05 13:47:05-05:00,"Bausch Health, l’ancien Valeant, paiera 94 millions$ pour régler une action collective","LAVAL - La pharmaceutique Bausch Health a indiqué mercredi avoir mis fin à d’importantes questions juridiques remontant à l’époque où elle portait le nombre de Valeant, en acceptant de payer 94 millions $, plus les frais d’administration, pour régler une action collective canadienne en valeurs mobilières.",BHC,fr,La Tribune
2020-08-05 12:50:29-05:00,Bausch Health versera 94 millions pour régler une action collective contre Valeant,(Laval) La pharmaceutique Bausch Health a indiqué mercredi avoir mis fin à d’importantes questions juridiques remontant à l’époque où elle portait le nombr…,BHC,fr,La Presse
2020-08-05 07:38:25-05:00,Bausch to pay $94-million plus costs to resolve Canadian securities class action,The action filed in Quebec Superior Court in 2015 alleged violations of Canadian securities laws over a stock plunge that hit investors about five years ago,BHC,en,The Globe and Mail
2020-08-05 06:00:00-05:00,Bausch Health Resolves Canadian Securities Class Action,"LAVAL, QC, Aug. 5, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company""), today announced that the parties in the Canadian securities class action (Cattuci et al. v. Valeant Pharmaceuticals International Inc. et. al., Court File No.:…",BHC,en,PR Newswire
2020-08-03 16:10:23-05:00,SEC’s Pathetic Agreement With Bausch Health Companies,"Whitney Tilson’s email to investors discussing SEC’s pathetic agreement with Bausch Health Companies Inc (NYSE:BHC) (formerly Valeant); Insys documentary; Opioids, Bribery, and Wall Street; Novartis bribery settlement; Kodak. Q2 2020 hedge fund letters, conferences and more SEC’s Pathetic Agreement With Bausch Health Companies 1) On Friday, the U.S. Securities and Exchange Commission (“SEC”) announced a […] The post SEC’s Pathetic Agreement With Bausch Health Companies appeared first on ValueWalk .",BHC,en,ValueWalk
2020-07-31 16:58:29-05:00,"Bausch Health, three former executives agree to penalties to resolve U.S. SEC charges","Bausch Health Companies Inc has agreed to pay $45 million, and three of former top executives also agreed to penalties, to settle charges of improper revenue recognition and misleading disclosures in U.S. regulatory filings, the U.S. Securities and Exchange Commission (SEC) said on Friday.",BHC,en,Reuters
2020-07-31 16:30:45-05:00,Bausch Health to pay $45 million fine to settle Philidor charges,Bausch Health Cos. undefined will pay a $45 million fine to settle charges that the company misled investors in financial statements when it was known as…,BHC,en,MarketWatch
2020-07-31 15:43:00-05:00,Bausch Health Resolves Legacy SEC Investigation,"LAVAL, QC, July 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company""), f/k/a Valeant Pharmaceuticals International, Inc. (""Valeant""), today announced the successful resolution of the legacy investigation by the U.S. Securities and…",BHC,en,PR Newswire
2020-07-24 13:15:00-05:00,COVID-19 Impacts: Non-Tumorous Skin Diseases Therapeutics Market will Accelerate at a CAGR of over 9% through 2020-2024 | Misdiagnosis of Skin Diseases to Boost Growth | Technavio,"Technavio has been monitoring the non-tumorous skin diseases therapeutics market and it is poised to grow by USD 12.93 billion during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200724005304/en/ Technavio has announced its latest market research report titled Global Non-Tumorous Skin Diseases Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request the Latest Free Sample Report on COVID-19 Impact Frequently Asked Questions- What is the year-over-year growth of the non-tumorous skin diseases therapeutics market in 2020? Technavio says that the year-over-year growth of the market is 7.19% in 2020.",BHC,en,Benzinga Feeds
2020-07-23 06:00:00-05:00,Bausch Health Companies Inc. Will Release Second-Quarter 2020 Financial Results On August 6,"LAVAL, QC, July 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") will release its second-quarter 2020 financial results on Thursday, Aug. 6, 2020. Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to…",BHC,en,PR Newswire
2020-07-15 05:41:00-05:00,"Microscopy Devices Market Study 2020-2025 with Profiles of Bausch Health, Bruker Corporation, Carl Zeiss, Thermofisher Scientific, and Olympus Corporation Amongst Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Microscopy Device Market - Growth, Trends, and Forecasts (2020 - 2025)"" report has been added to ResearchAndMarkets.com's offering. The market for microscopy devices is being driven by factors such as a rising number of inventions in the field of microscopy, growing focus on nanotechnology and life science research. Several studies have suggested that microscopy was seen performing better than the rapid diagnostics test (RDT) in the diagnosis of malaria in children",BHC,en,Business Wire
2020-07-06 08:30:00-05:00,"Global Contact Lens Market Study 2020-2025 Featuring Profiles of Major Players Essilor Int'l, Novartis, Bausch Health Companies, Zeiss Group, and the Cooper Companies Amongst Others","DUBLIN, July 6, 2020 /PRNewswire/ -- The ""Contact Lens Market- Growth, Trends, and Forecast (2020 - 2025)"" report has been added to ResearchAndMarkets.com's offering. The global contact lens market is projected to register a CAGR of 5.92% during the forecast period, 2020 to 2025. In order…",BHC,en,PR Newswire
2020-07-01 20:00:00-05:00,"Upadhye Cwik Client ECI Pharma Successfully Fended off Valeant Pharma's Challenges in Court, at the FDA, and in ITC proceedings","CHICAGO, July 1, 2020 /PRNewswire/ --Upadhye Cwik LLP prides itself as an innovative law firm that can provide efficient and effective legal representation to large and small pharmaceutical and device companies alike. Upadhye Cwik takes an integrative approach to problem solving, and is…",BHC,en,PR Newswire
2020-06-23 06:00:00-05:00,"Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, 0.045%, In The United States","ARAZLO™ (tazarotene) Lotion, 0.045% is Indicated for the Topical Treatment of Acne Vulgaris in Patients Nine Years of Age and Older LAVAL, QC, June 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest…",BHC,en,PR Newswire
2020-06-16 06:00:00-05:00,Bausch Health to Participate at Goldman Sachs Annual Leveraged Finance Conference,"LAVAL, Quebec, June 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Paul S. Herendeen, executive vice president and chief financial officer, Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, and William…",BHC,en,PR Newswire
2020-06-15 06:00:00-05:00,Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients,"LAVAL, QC, June 15, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals (""Salix""), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI)…",BHC,en,PR Newswire
2020-06-13 16:45:45-05:00,3 Reasons to Buy Bausch Health (TSX:BHC) Stock,Bausch Health stock continues to drive product approvals and debt reduction and is armed with a strong portfolio of health products. The post 3 Reasons to Buy Bausch Health (TSX:BHC) Stock appeared first on The Motley Fool Canada .,BHC,en,The Motley Fool Canada
2020-06-11 06:13:35-05:00,BRIEF-Health Canada Issues Notice Of Compliance For Bausch Health's DUOBRII,Bausch Health Companies Inc:,BHC,en,Reuters
2020-06-11 06:00:00-05:00,"Santé Canada émet un avis de conformité pour DUOBRII(MC), de Bausch Health","/CNW Telbec/ - Bausch Health, Canada, qui fait partie de Bausch Health Companies inc. (NYSE: BHC) (TSX: BHC), (« Bausch Health » ou « la Société ») a annoncé…",BHC,fr,Canada Newswire
2020-06-11 06:00:00-05:00,Health Canada Issues Notice of Compliance for Bausch Health's DUOBRII™,"/CNW Telbec/ - Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), (""Bausch Health"" or the ""Company"") has announced…",BHC,en,Canada Newswire
2020-06-06 10:31:43-05:00,Bausch (BHC) Up 21.2% Since Last Earnings Report: Can It Continue?,Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BHC,en,Zacks Investment Research
2020-05-27 06:00:00-05:00,Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses,"LAVAL, Quebec, May 27, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health""), today announced the European launch of the company's first Extended Depth of Focus intraocular lens (IOL), LuxSmart™, and a…",BHC,en,PR Newswire
2020-05-22 18:00:00-05:00,Anterix and Bausch Holding See Activist Action,"Owl Creek Asset Management increased its stake in wireless-communications firm Anterix, while Paulson & Co. bought more Bausch stock.",BHC,en,Barron's
2020-05-21 06:00:00-05:00,Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference,"LAVAL, Quebec, May 21, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate…",BHC,en,PR Newswire
2020-05-17 09:25:07-05:00,"Notable Insider Buys: Bausch, TransDigm And More","Insider buying can be an encouraging signal for potential investors. Directors stepped up to make sizable share purchases last week. Some of those transactions came in the wake of earnings reports. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty. Insiders continued to add shares despite overall market volatility and global economic gloom. Here are some of the most noteworthy insider purchases reported in the past week. TransDigm A TransDigm Group Incorporated (NYSE: TDG ) director indirectly added almost 372,000 shares of this aircraft component maker to his stake. At per-share prices ranging from $309.87 to $354.34, that … Full story available on Benzinga.com",BHC,en,Benzinga Feeds
2020-05-14 16:00:26-05:00,Why Bausch Health (TSX:BHC) Stock Is a Smart Risk to Take,"Bausch Health (TSX:BHC)(NYSE:BHC) stock falls, as guidance is reduced due to coronavirus disruptions, but if we look beyond this temporary setback, we can see promise. The post Why Bausch Health (TSX:BHC) Stock Is a Smart Risk to Take appeared first on The Motley Fool Canada .",BHC,en,The Motley Fool Canada
2020-05-11 15:20:00-05:00,Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Prepayment Of Term Loan 2022 Mandatory Amortization,"LAVAL, Quebec, May 11, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") announced today that it has priced and upsized its previously announced offering of $1,500,000,000 aggregate principal amount of 6.250% senior notes due 2029 (the…",BHC,en,PR Newswire
2020-05-08 17:43:00-05:00,"Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed",Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.,BHC,en,Zacks Investment Research
2020-05-08 06:30:00-05:00,COVID-19 Impact and Recovery Analysis- Global Chemical Peel Market 2020-2024 | Evolving Opportunities with Allergan Plc and Bausch Health Companies Inc. | Technavio,"LONDON--(BUSINESS WIRE)-- #ChemicalPeelMarket--The chemical peel market is poised to grow by 62.78 mn during 2020-2024, according to Technavio",BHC,en,Business Wire
2020-05-07 16:25:49-05:00,Bausch Health reports $152-million first-quarter loss due to COVID-19,Shares of Bausch Health fell more than eight per cent as the company lowered its 2020 forecast,BHC,en,The Globe and Mail
2020-05-07 16:04:33-05:00,Pandemic cuts into Bausch Health sales as company posts US$152-million loss,No summary available.,BHC,en,The Star
2020-05-07 07:53:02-05:00,Infographic: Highlights of Bausch Health (BHC) Q1 2020 earnings results,"Bausch Health Companies Inc. (NYSE: BHC) reported a wider loss in the first quarter of 2020 due to lower income taxes benefit and higher costs and expenses. The top-line remained virtually unchanged from the last year, due to the negative impact of COVID-19 pandemic, unfavorable foreign exchange, the impact of 2019 acquisition, as well as […]",BHC,en,news.alphastreet.com
2020-05-07 06:54:04-05:00,Bausch Health's stock drops after a surprise decline in revenue and lowered outlook,"Shares of Bausch Health Companies Inc. undefined sank 3.6% in premarket trading Thursday, after the drug and medical-device products maker reported a wider…",BHC,en,MarketWatch
2020-05-07 05:59:00-05:00,Bausch Health Companies Inc. Announces First-Quarter 2020 Results,"LAVAL, Quebec, May 7, 2020 /PRNewswire/ -- First-Quarter 2020 Financial Results Revenues of $2.012 Billion GAAP Net Loss of $152 Million Adjusted EBITDA (non-GAAP)1 of $813 Million GAAP Cash Generated from Operations of $261 Million Bausch + Lomb/International Segment Reported Revenue Was…",BHC,en,PR Newswire
2020-05-06 09:07:35-05:00,BRIEF-Bausch Health And Alfasigma Announce Resolution Of Xifaxan Intellectual Property Litigation,Bausch Health Companies Inc:,BHC,en,Reuters
2020-05-06 06:00:00-05:00,Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation,"/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") along with its wholly owned subsidiary, Salix Pharmaceuticals…",BHC,en,PR Newswire
2020-05-04 07:38:22-05:00,"Class Members Opting Out Of Secondary-Market Liability Class Actions And Instituting Their Own Claims – Are There Prescription Or Forfeiture Defences Available Under The Quebec Regime? - Litigation, Mediation & Arbitration - Canada","The Quebec Superior Court, in California States Teachers' Retirement System v. Bausch Health Companies Inc. (2020 QCCS 275), …",BHC,en,Mondaq
2020-05-02 13:30:56-05:00,Why Bausch Health’s Stock Price Rose 15.3% in April,"Bausch Health's stock price rises, as its drug enters testing for the treatment of coronavirus, and as investors flock to defensive healthcare stocks. The post Why Bausch Health’s Stock Price Rose 15.3% in April appeared first on The Motley Fool Canada .",BHC,en,The Motley Fool Canada
2020-04-30 11:34:41-05:00,Bausch Health (BHC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release,Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BHC,en,Zacks Investment Research
2020-04-30 06:00:00-05:00,Bausch Health To Participate at 2020 Bank of America Merrill Lynch Global Healthcare Conference,"LAVAL, Quebec, April 30, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to…",BHC,en,PR Newswire
2020-04-29 17:00:00-05:00,Analysis on New Product Launches in Covid-19 Related Markets-Global Sinus Dilation Devices Market 2020-2024 | Evolving Opportunities with Bausch Health Companies Inc. and Dalent LLC | Technavio,LONDON--(BUSINESS WIRE)-- #GlobalSinusDilationDevicesMarket--The sinus dilation devices market size has the potential to grow by USD 1.37 billion during 2020-2024,BHC,en,Business Wire
2020-04-29 15:50:00-05:00,Bausch Health Announces 2020 Annual Meeting Of Shareholder Results,"LAVAL, Quebec, April 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders held on April 28, 2020. The detailed results of the vote…",BHC,en,PR Newswire
2020-04-29 06:56:56-05:00,"Cosmeceuticals Market in Demand; Sentiment Is Shifting Towards Growth | L'Oreal, Bausch Health Companies, ZO Skin Health",What's Ahead in the Global Cosmeceuticals Market? Benchmark yourself with strategic steps and conclusions recently published by AMA,BHC,en,EIN News
2020-04-29 06:00:00-05:00,"FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old","LAVAL, Quebec, April 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. Food and Drug Administration (FDA) has approved a…",BHC,en,PR Newswire
2020-04-28 06:00:00-05:00,Bausch Health Issues Form 8-K For 2020 Annual Meeting Of Shareholders Presentation,"LAVAL, Quebec, April 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") today announced the Company is providing a presentation (the ""2020 Annual Meeting of Shareholders"") on its business during the Company's annual meeting of…",BHC,en,PR Newswire
2020-04-23 06:00:00-05:00,Bausch Health Companies Inc. Will Release First-Quarter 2020 Financial Results On May 7,"LAVAL, Quebec, April 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") will release its first-quarter 2020 financial results on Thursday, May 7, 2020. Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to…",BHC,en,PR Newswire
2020-04-14 10:06:00-05:00,"Worldwide Aesthetic Lasers and Energy Devices Industry to 2025 - Featuring Allergan, Bausch Health & Cutera Palomar Medical Technologies Among Others - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Aesthetic Lasers and Energy Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025"" report has been added to ResearchAndMarkets.com's offering. The global aesthetic lasers and energy devices market reached a value of US$ 3,786 Million in 2019. Aesthetic lasers and energy devices are the medical devices that are used for numerous cosmetic procedures to treat skin defects and improve the physical appearance of an individual. U",BHC,en,Business Wire
2020-04-14 08:55:00-05:00,Bausch (BHC) Starts Study on Virazole for Coronavirus Infection,Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.,BHC,en,Zacks Investment Research
2020-04-09 03:04:22-05:00,Bausch Health Companies Inc. (NYSE: BHC) Q4 2019 Earnings Call Transcript | AlphaStreet,Final earnings conference call transcript of Bausch Health Companies Inc. - BHC stock,BHC,en,news.alphastreet.com
2020-03-19 06:37:15-05:00,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.","BFRA,BEAT,BHC,BIOL,BDSI,BDTX",en,Benzinga
2020-03-17 17:40:29-05:00,Bausch Health CEO’s 2019 pay climbs to US$17.14-million,Stock and options worth nearly US$12.3-million drove Joseph Papa’s compensation,BHC,en,The Globe and Mail
2020-03-13 10:43:00-05:00,Dispensed: Why the US healthcare system could be pushed to its limits during the coronavirus pandemic,"Hello, Greetings from Brooklyn, where the pup is happy we're working from home, and the streets are starting to get eerily quiet. You're reading Dispensed, Business Insider's weekly healthcare newsletter, where we're doing our best to social distance and keep you up to date on what's going on with the coronavirus pandemic. Are you new to the newsletter ? You can sign up here . Over the course of the week, we've seen states and cities around the US take some pretty drastic moves in the hopes of halting the spread of the novel coronavirus. Sports have been canceled, Disneyland closes Saturday, and Broadway has been mandated to go dark until mid-April. ( Read on to see why canceling these events and helping to #flattenthecurve could be key to keeping the effects of this outbreak within the bounds of the US healthcare system.) Over here on the healthcare team, we've been working hard (from home) to get a sense of how the response to the outbreak has been going within the US health system. ",BHC,en,Business Insider
2020-03-13 06:52:53-05:00,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.","BEAM,BEAT,BHC,BDTX,BDSI",en,Benzinga
2020-03-11 13:21:00-05:00,Big Pharma just pulled the plug on its first attempt to copy the buzzy startups that ship Viagra and hair-loss pills to your door,"Bausch Health abruptly stopped offering prescriptions on its site Dermatology.com. The website offered drugs online to treat conditions like acne, wrinkles, and eczema, and launched just weeks ago. Bloomberg's Emma Court, who first reported the news, said that the move came after hundreds of dermatologists signed a petition to Bausch Health asking the company to shut down its service. The $9 billion drugmaker was following a strategy similar to buzzy startups like Roman and Hims, which use online doctor visits to prescribe Viagra and hair-loss pills online. ""I believe that we are ahead of a mega-trend here,"" Bill Humphries, president of Bausch's Ortho Dermatologics business, told Business Insider in February. A Bausch Health spokesperson confirmed Wednesday to Business Insider that the site will not include patient consultations when it returns. Visit Business Insider's homepage for more stories . Bausch Health abruptly shut down prescribing through its Dermatology.com website just weeks after launching it.",BHC,en,Business Insider
2020-03-11 07:03:52-05:00,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.","BHC,BDTX",en,Benzinga
2020-03-10 08:19:55-05:00,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.","BHC,BDTX",en,Benzinga
2020-03-07 14:36:13-05:00,Why the Bausch Health (BHC) Stock Price Fell 18.1% in February,The coronavirus negatively impacts Bausch Health stock price as revenue guidance disappoints and investors flock to safety. The post Why the Bausch Health (BHC) Stock Price Fell 18.1% in February appeared first on The Motley Fool Canada .,BHC,en,The Motley Fool Canada
2020-03-03 07:02:22-05:00,These Two Drug Stocks are Dirt Cheap,The market’s freefall in the last week led to the blatant of good companies. Bausch Health (NYSE:BHC) lost 16.5% last week while Teva Pharmaceuticals (NYSE:TEVA) also dropped. Both drug delivery firms now trade at similar valuations of a forward P/E …,BHC,en,Baystreet.ca
2020-02-21 10:48:27-05:00,"Dispensed: Big Pharma's plans to compete with buzzy startups, Sanofi's entrance to the coronavirus vaccine race, and a Medicare Advantage pitch deck","Hello, Welcome to Dispensed, Business Insider's weekly healthcare newsletter. This week's edition is being written in sunny Palm Springs, California, though regrettably sent out back in chilly New York. Are you new to the newsletter ? You can sign up here. The big story I want to highlight this week came from a tag-team between Andrew Dunn and me . We got the scoop on Dermatology.com, the website pharmaceutical company Bausch Health (remember Valeant Pharmaceuticals?) is using to get in on the trend of startups that are prescribing and shipping medication straight to your door. Ever since I first started hearing about companies like Roman, Hims, or Nurx, I've been thinking it'd only be a matter of time before drugmakers themselves see this as a new way to reach patients. And when they do get interested, who are the companies they'll need to work with to pull that off? What Bausch is doing with its dermatology drugs gives us a good idea of what we might expect. Big Pharma just started copying the buzzy startups that ship Viagra and hair-loss pills to your door, and it could be the start of a 'mega-trend' The pharmaceutical company Bausch Health is now selling prescription drugs online to treat conditions like acne, wrinkles, and eczema.",BHC,en,Business Insider
2020-02-20 02:36:21-05:00,Bausch Health (BHC) Drops More than 10% After Q4 Results,Bausch Health (BHC) drops more than 10% after reporting Q4 results. Elliiott Wave technical outlook suggests however it can bounce soon.,BHC,en,Elliottwave Forecast
2020-02-19 17:18:01-05:00,Health Care Up Amid Mixed Earnings -- Health Care Roundup | MarketScreener,"Health-care companies rose amid mixed earnings. Shares of specialty drug maker Bausch Health fell after it reported a fourth-quarter loss, reflecting money set aside for legal costs. Bausch… | February 19, 2020",BHC,en,MarketScreener
2020-02-19 15:01:48-05:00,Bausch Health Earnings: BHC Stock Takes a Big 7% Hit on Mixed Q4,Bausch Health (BHC) earnings for the pharmaceutical company's fourth quarter of 2019 have BHC stock falling hard on Wednesday.,BHC,en,InvestorPlace
2020-02-19 12:11:05-05:00,Bausch Shares Fall on Wider Loss Reflecting Legal Reserve,"Bausch Health shares are lower after the medical-devices producer reported a wider fourth-quarter loss, reflecting a reserve for legal costs.",BHC,en,The Street
2020-02-19 08:25:02-05:00,Bausch Health (BHC) Meets Q4 Earnings Estimates,"Bausch (BHC) delivered earnings and revenue surprises of 0.00% and -0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?",BHC,en,Zacks Investment Research
2020-02-19 08:10:39-05:00,Bausch Health reports US$1.52B Q4 loss due to stock drop lawsuit settlement,No summary available.,BHC,en,The Star
2020-02-19 06:59:00-05:00,Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance,"LAVAL, Quebec, Feb. 19, 2020 /PRNewswire/ -- Fourth-Quarter 2019 Financial Results Revenues of $2.224 Billion GAAP Cash Generated from Operations of $234 Million GAAP Net Loss of $1.516 Billion Adjusted EBITDA (non-GAAP)1 of $898 Million Full-Year 2019 Financial Results Revenues of $8.601…",BHC,en,PR Newswire
2020-02-18 14:50:01-05:00,Bausch Health Looks a Little Blurry Ahead of Earnings,Bausch Health Looks a Little Blurry Ahead of Earnings…BHC,BHC,en,TheStreet
2020-02-18 07:00:00-05:00,"Ortho Dermatologics Launches Telemedicine on Dermatology.com, U.S. Cash-Pay Prescription Program","Patients Can Now Use Site to Consult with Qualified Health Care Professionals On-Demand, Order and Potentially Receive Dermatologist-Recommended Skin Care Products BRIDGEWATER, N.J., Feb. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business,…",BHC,en,PR Newswire
2020-02-12 12:31:04-05:00,Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?,Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BHC,en,Zacks Investment Research
2020-02-12 07:00:00-05:00,Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations,"LAVAL, Quebec, Feb. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") announced today it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations. Bausch Health will…",BHC,en,PR Newswire
2020-02-11 17:00:39-05:00,Is Bausch Health Companies (TSX:BHC) a Buy?,"Bausch Health Companies (TSX:BHC)(NYSE:BHC) has made impressive gains over the past two years, while slashing its debt. Does this mean that the company is now a solid option to consider?",BHC,en,The Motley Fool Canada
2020-02-04 10:49:02-05:00,Why the Bausch Health (BHC) Stock Price Fell 6.6% in January,Bausch Health Companies Inc. (TSX:BHX) (NYSE:BHC) stock price falls in January as investors focus on valuation.,BHC,en,The Motley Fool Canada
2020-02-03 07:00:00-05:00,Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program,"Students Treated for Dermatologic Conditions Can Apply for the Scholarship Through April 27, 2020 LAVAL, Quebec, Feb. 3, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health…",BHC,en,PR Newswire
2020-01-29 08:05:31-05:00,Why TSX Stocks May Be a Better Bet Than the S&P 500 in the 2020s,Bausch Health Companies (TSX:BHC)(NYSE:BHC) and other TSX Index stocks that could give you the most bang for your buck in the new decade.,BHC,en,The Motley Fool Canada
2020-01-28 07:00:00-05:00,Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology,"LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and…",BHC,en,PR Newswire
2020-01-27 11:20:09-05:00,"Bill Miller's mutual fund crushed the market for a record 15 straight years, and he's still beating his peers. He outlined for us the top 4 contrarian bets he's making right now.","Mutual fund manager Bill Miller is famous for beating the stock market for a record 15 years in a row in the 1990s and 2000s, and he's maintained his sterling track record since then. Known as one of the great value investors, Miller focuses on companies that he believes are trading for much less than they are really worth. Asked about his most surprising contrarian investments, Miller named several groups of stocks that endured huge drops because of issues like public controversies or high levels of debt. Click here for more BI Prime stories . Long after the conclusion of his famous winning streak, and long after his style of investing became unfashionable, Bill Miller has continued to beat the market. Miller gained fame by beating the stock market for 15 consecutive years ending in 2006, a record he still owns. Today he's bringing in huge returns at Miller Value Partners , which manages $2.6 billion. For context, his Miller Opportunity Trust beat 99% of its peers over the past 3 years and has handily beaten the S&P 500 since its inception in 1999.",BHC,en,Business Insider
2020-01-22 07:10:21-05:00,Wells upgrades Bausch Health in premarket analyst action,ArTara Therapeutics (NASDAQ:TARA) initiated with Buy rating at Ladenburg Thalmann. Cue Biopharma (NASDAQ:CUE) initiated with Market Perform rating and $22,BHC,en,Seeking Alpha
2020-01-17 03:30:00-05:00,Should Value Investors Pick Bausch Health (BHC) Stock Now?,Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.,BHC,en,Zacks Investment Research
2020-01-16 07:00:00-05:00,Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19,"LAVAL, Quebec, Jan. 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"") will release its fourth-quarter and full-year 2019 financial results on Wednesday, Feb. 19, 2020. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to…",BHC,en,PR Newswire
2020-01-13 07:00:00-05:00,Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference,"LAVAL, Quebec, Jan. 13, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the ""Company"") has published a brief company update presentation designed to complement remarks that will be provided by management during a fireside chat at 1:30 p.m. PT (4:30 p.m. ET) today during…",BHC,en,PR Newswire
2020-01-08 20:00:00-05:00,Global Liposuction Devices Market 2019-2023| Evolving Opportunities with Alma Lasers and Bausch Health | Technavio,"LONDON--(BUSINESS WIRE)-- #BauschHealth--The global liposuction devices market is poised to grow by USD 4.82 billion during 2019-2023, according to Technavio",BHC,en,Business Wire
2020-01-07 15:13:02-05:00,Famed short-seller Andrew Left's hedge fund saw 43% returns in its 1st year,"Citron Capital, the new hedge fund led by famed short-seller Andrew Left, gained 43% net of fees in 2019, Reuters reported Monday, citing a letter to investors. The fund includes both long and short positions. In 2019, the average exposure was 75.8% long and 80.3% short, Reuters reported, citing Left's letter to investors. Left also told investors that he's sticking to his bet against Peloton. In December, he gave the company a $5 price target , betting it will fall as much as 83% in a year. Read more on Business Insider. Citron Capital, the new hedge fund led by Andrew Left, had a solid first year. Left, the famed market-moving short-seller and leader of Citron Research, told investors on Monday that the hedge fund had a net return of 43% in 2019, its first year open, Reuters reported . The fund contains both long positions on companies Left sees poised to gain, and short positions against companies he thinks will fall. In 2019, the average exposure was 75.8% long and 80.3% short, Reuters reported, citing Left's letter to investors.",BHC,en,Business Insider
2020-01-07 02:49:08-05:00,Citron Names Top Long And Short Ideas For 2020,"In the ""annual investor letter for 2019"" published Monday, Citron Capital LLC managing partner Andrew Left named his top picks for long and short ideas for the year 2020. RH Headed For Acquisition The activist short-seller picked home furnishings company RH (NYSE: RH ) as the best long bet, claiming that it is headed for acquisition in 2020. The California-based company was also one of the biggest winners for Citron, alongwith Bausch Health Companies Inc. (NYSE: BHC ) and Snap Inc. (NYSE: SNAP ), the letter said. According to Left, potential buyers for RH could include French luxury goods giant LVMH Moet Hennessy Louis Vuitton SE (OTC: LVMUY ), e-commerce giant Amazon.com Inc. (NASDAQ: AMZN ), and Berkshire Hathaway Inc. … Full story available on Benzinga.com",BHC,en,Benzinga
2020-01-06 09:00:00-05:00,Global Ophthalmology Devices Market 2019-2023| Evolving Opportunities with Alcon Inc. and Bausch Health Companies Inc. | Technavio,"LONDON--(BUSINESS WIRE)-- #HealthcareDevices--Global ophthalmology devices market is poised to grow by USD 13.9 billion during 2019-2023, progressing at a CAGR of close to 4%.",BHC,en,Business Wire
2020-01-06 07:00:00-05:00,Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference,"LAVAL, Quebec, Jan. 6, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 13, 2019 at…",BHC,en,PR Newswire
2019-12-20 06:45:00-05:00,"Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark","Ortho Dermatologics Will Maintain Market Exclusivity for BRYHALI Lotion Until 2026¹ LAVAL, Quebec, Dec. 20, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") and its dermatology business, Ortho Dermatologics, one of the largest…",BHC,en,PR Newswire
2019-12-19 06:59:00-05:00,"FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris","First Tazarotene Acne Treatment Approved in Lotion Formulation BRIDGEWATER, N.J., Dec. 19, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today…",BHC,en,PR Newswire
2019-12-18 16:30:00-05:00,Bausch Health Announces Conditional Redemption Of Existing Senior Notes,"LAVAL, Quebec, Dec. 18, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") announced that it issued today a conditional notice of redemption for $1.240 billion aggregate principal amount of the Company's outstanding 5.875% Senior Notes due…",BHC,en,PR Newswire
2019-12-17 07:15:00-05:00,Bausch Health Announces Launch Of Private Offering Of Senior Notes,"LAVAL, Quebec, Dec. 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company"") announced today that it has launched an offering of a combined $1,250,000,000 aggregate principal amount of new senior notes due 2028 (the ""2028 Notes"") and new…",BHC,en,PR Newswire
2019-12-16 12:28:15-05:00,Bausch Health announces $1.21-billion settlement over stock plunge,No summary available.,BHC,en,The Star
2019-12-16 09:31:32-05:00,Bausch Health plans $1.21 B settlement over stock plunge,"Bausch Health, once known as Valeant Pharmaceuticals, will pay more than $1 billion to settle litigation over a stock plunge that investors suffered after it became the poster child of drug company price gouging several years ago",BHC,en,ABC News
2019-12-16 08:01:00-05:00,Bausch Health agrees to pay $1.21 billion to settle share price lawsuit,https://www.investing.com/news/stock-market-news/bausch-health-agrees-to-pay-121-billion-to-settle-share-price-lawsuit-2041949,BHC,en,Investing.com
2019-12-16 07:00:00-05:00,"Bausch Health Resolves ""Stock Drop"" Litigation Initially Filed in October 2015","LAVAL, Quebec, Dec. 16, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (""Bausch Health"" or the ""Company""), today announced that the parties in the putative securities class action Valeant Pharmaceuticals International, Inc. Securities Litigation (Case No. 3:15-cv-07658)…",BHC,en,PR Newswire
2019-12-13 08:10:02-05:00,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.","BHC,BIO,BIO.B",en,Benzinga Feeds
2019-12-12 08:51:30-05:00,"Top Analyst Upgrades and Downgrades: Autodesk, Bausch Health, Charles Schwab, Darden Restaurants, GE, Home Depot, Kroger, Merit Medical, Monolithic Power, Starbucks and More",No summary available.,BHC,en,24/7 Wall street
2019-12-12 07:38:44-05:00,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.","BHC,BIO,BIO.B",en,Benzinga
2019-12-11 08:30:00-05:00,Bausch + Lomb Introduces enVista® Toric MX60ET Intraocular Lens With StableFlex™ Technology,"BRIDGEWATER, N.J., Dec. 11, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced the introduction of the enVista® toric MX60ET hydrophobic acrylic intraocular lens (IOL) with StableFlex™ technology, which…",BHC,en,PR Newswire
2019-12-11 07:21:31-05:00,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL )(agreed to be bought by Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Bristol-Myers Squibb Co (NYSE: BMY )(reacted to ASH presentation) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GlaxoSmithKline plc (NYSE: GSK ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) The Medicines Company (NASDAQ: MDCO ) Merck & Co.",BHC,en,Benzinga
2019-12-10 15:30:00-05:00,Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023 | Evolving Opportunities with AstraZeneca and Bausch Health | Technavio,LONDON--(BUSINESS WIRE)-- #cytomegalovirustherapeutics--Technavio has been monitoring the cytomegalovirus (CMV) therapeutics market which will grow by USD 241 million during 2019-2023 at a CAGR of 5%,BHC,en,Business Wire
2019-12-10 07:56:02-05:00,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares","The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.","BHC,BIOC",en,Benzinga
2019-12-05 13:40:00-05:00,"Opportunities in Global Ophthalmic Surgery Markets, 2019 & Beyond - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Opportunities in Global Ophthalmic Surgery Markets"" report has been added to ResearchAndMarkets.com's offering. Coverage in this report includes a detailed analysis of the current and forecast markets for ophthalmic surgery technologies. Current Market Size & Forecast Competitive Landscape Supplier Revenues & Market Shares Current & Emerging Technologies Market Trends & Opportunities Plus More Competitors Covered: Bausch Health/Valeant Carl Zeiss Me",BHC,en,Business Wire
2019-12-05 10:46:28-05:00,"Bausch Health, JetBlue And More 'Fast Money' Picks For Dec. 5","On CNBC's ""Fast Money Final Trade,"" Pete Najarian said JetBlue Airways Corporation (NASDAQ: JBLU ) is going higher. He explained that there was a huge call options buying in the name on Wednesday. Tim Seymour thinks the fundamentals of the energy space are improving. He is a buyer … Full story available on Benzinga.com",BHC,en,Benzinga Feeds
2019-12-05 07:14:16-05:00,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of strategic options, including a potential sale) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bausch Health Companies Inc (NYSE: BHC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Incyte Corporation (NASDAQ: INCY ) Inspire Medical Systems Inc (NYSE: INSP ) IVERIC bio Inc (NASDAQ: ISEE ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co.","BHC,BIO,BIO.B",en,Benzinga
2019-12-04 23:45:00-05:00,"Bausch Health (BHC) Hits A New High, What Next?","Shares of Bausch Health Companies Inc. (BHC) (BHC.TO), which are up 55 percent year-to-date, closed at an all-time high of $28.68 yesterday..",BHC,en,RTT News
2019-12-04 11:30:46-05:00,Why Is Bausch (BHC) Up 8.2% Since Last Earnings Report?,Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BHC,en,Zacks Investment Research
2019-11-14 08:07:04-05:00,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).",BHC,en,Benzinga
2019-11-13 08:00:00-05:00,Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation,"Benches, Tables, Waste Stations and an Agility Ramp Will Help Train Guide Dogs for the Blind or Visually Impaired BRIDGEWATER, N.J., Nov. 13, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TXS: BHC), in collaboration with…",BHC,en,PR Newswire
2019-11-12 06:12:00-05:00,Will Bausch Health Continue to Surge Higher?,"As of late, it has definitely been a great time to be an investor Bausch Health.",BHC,en,Zacks Investment Research
2019-11-11 07:49:54-05:00,Canada’s Best Turnaround Stock Can Make You a Billionaire,Bausch Health Companies Inc (TSX:BHC) has seen a phenomenal turnaround under new CEO Joseph Papa. Can investors expect to see big gains in the stock price as the company deleverages and increases profit margins?,BHC,en,The Motley Fool Canada
2019-11-06 09:10:11-05:00,Is Bausch Health (BHC) Stock Undervalued Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",BHC,en,Zacks Investment Research
2019-11-05 12:00:17-05:00,Bausch Health (TSX:BHC) Blows Away Expectations Once Again,"Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) raised guidance again, as third-quarter 2019 revenue and margins come in better than expected.",BHC,en,The Motley Fool Canada
2019-11-04 10:44:31-05:00,Bausch Analyst Sees Challenging Setup For Next Leg Of Recovery Story,"Bausch Health Companies Inc (NYSE: BHC ) reported Monday ahead of the market open with better-than-expected third-quarter revenue and higher non-GAAP earnings. The company also raised its fiscal year 2019 guidance. The Analyst Bank of America Merrill Lynch analyst Jason Gerberry reiterated an Underperform rating and $19 price target. The Takeaways Bausch's revenue beat was driven by better Xifaxan price tailwinds and the outperformance of diversified brands, Gerberry said in a Monday note. (See his track record here .) With both segments having high margins, the company achieved strong margins, P&L leverage and a mid-to high-single-digit beat on EBITDA, the … Full story available on Benzinga.com",BHC,en,Benzinga
2019-11-04 10:13:13-05:00,"Bausch Health reports $49-million third-quarter loss, raises full-year financial guidance","On an adjusted basis, Bausch earned net income of $425-million in the quarter compared with $403-million for the third quarter of 2018",BHC,en,The Globe and Mail
2019-11-04 09:17:50.870000-05:00,"Bausch Health reports $49M Q3 loss, raises full-year financial guidance | The Star","The drug company says it now expects full-year revenue in a range from $8.40 billion to $8.60 billion, up from earlier expectations for revenue between $8.475 and $8.625 billion.",BHC,en,The Star
2019-11-04 07:40:02-05:00,Bausch Health : Raises Forecasts for 2019 | MarketScreener,"By Micah Maidenberg Bausch Health Companies Inc. on Monday said it expects to generate $8.48 billion to $8.63 billion in revenue for the full year. Previously, the company forecast… | November 4, 2019",BHC,en,MarketScreener
2019-11-04 07:23:00-05:00,Bausch Health loss narrows in latest quarter,"Bausch Health Cos. Inc. said Monday it had a met loss of $49 million, or 14 cents a share, in the third quarter, after a loss of $350 million, or $1.00 a…",BHC,en,MarketWatch
2019-11-04 07:17:44-05:00,2 Canadian Millionaire-Maker Stocks on Sale!,BlackBerry (TSX:BB)(NYSE:BB) and Bausch Health Companies (TSX:BHC)(NYSE:BHC) are severely undervalued turnaround plays that are still misunderstood by the market.,BHC,en,The Motley Fool Canada
2019-11-04 06:59:00-05:00,Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges,"LAVAL, Quebec, Nov. 4, 2019 /PRNewswire/ -- Third-Quarter 2019 Financial Results Revenues of $2.209 Billion GAAP Net Loss of $49 Million Adjusted EBITDA (non-GAAP)1 of $942 Million GAAP Cash Generated from Operations of $515 Million Delivered Total Company Reported Revenue Growth of 3%…",BHC,en,PR Newswire
2019-11-04 05:54:35-05:00,"Earnings Scheduled For November 4, 2019","Companies Reporting Before The Bell Sysco Corporation (NYSE: SYY ) is expected to report its Q1 earnings at $0.97 per share on revenue of $15.50 billion. Bausch Health Companies Inc. (NYSE: BHC ) is projected to report its Q3 earnings at $1.07 per share on revenue of $2.16 billion. Sprint Corporation (NYSE: S ) is expected to report its Q4 loss at $0.02 per share on revenue of $8.17 billion. Under Armour, Inc. (NYSE: UAA ) is projected to report its Q4 earnings at $0.18 per share on revenue of $1.41 billion. FirstEnergy Corp. (NYSE: FE ) is estimated to report its Q3 earnings at $0.73 per share on revenue of $2.89 billion. Ryanair Holdings plc (NASDAQ: RYAAY ) is projected to report its Q4 earnings at $4.04 per share on revenue of $3.29 billion. Regal Beloit Corporation (NYSE: RBC ) is expected to report its Q4 earnings at $1.33 per share on revenue of $808.95 million. Insperity, Inc. (NYSE: NSP ) is estimated to report its Q4 earnings at $1.01 per share on revenue of $1.04 billion. Gannett Co., Inc. (NYSE: GCI ) is projected to report its Q3 earnings at $0.03 per share on revenue of $654.61 million.",BHC,en,Benzinga Feeds
2019-10-30 05:55:00-05:00,Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary,"Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019 BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals (""Salix""), one of the largest…",BHC,en,PR Newswire
2019-10-28 09:32:32-05:00,Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for,Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BHC,en,Zacks Investment Research
2019-08-06 06:18:00-05:00,"Bausch Health's stock surges as revenue rises in line with expectations, but outlook raised","Shares of Bausch Health Companies Inc. rallied 3.0% in premarket trading Tuesday, after the health care products company reported second-quarter revenue that…",BHC,en,MarketWatch
2019-07-29 07:07:00-05:00,Bausch Health to reduce debt by additional $100 million using cash flow from operations,Bausch Health Companies Inc. said Monday morning that it would be using cash flow from operations to pay down $100 million of its senior secured term loans…,BHC,en,MarketWatch
2019-07-18 18:35:33-05:00,Teva loses challenge to Bausch patent on drug Relistor,Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.,BHC,en,Reuters
2019-05-22 07:49:00-05:00,Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries,Which of these fallen stars has the more compelling comeback story?,BHC,en,The Motley Fool
2019-05-07 07:45:00-05:00,Glaucoma Treatment and Therapeutics Market Projected to Have Strong Growth Rate Through 2028,"PALM BEACH, Florida , May 7, 2019 /PRNewswire/ -- The patient demand for a better way to treat to glaucoma has been growing for years. Two recent reports from Transparency Market Research show that this growing worldwide consumer demand projects ever increasing revenues for both the Treatment and Therapeutic markets and for hope for the consumers for a better solution. The reports said: ""A new exhaustive report collated by Transparency Market Research envisages an average growth for the global glaucoma treatment market in the period between 2017 and 2026. More than US$ 3,300 revenues are expected to be gained from treatment of glaucoma across the globe by 2026-end… (and) The global glaucoma therapeutics market was valued at US$ 5,932.6 Mn in 2017 is anticipated to reach US$ 7,659.8 Mn by 2026, expanding at a CAGR of 2.9% from 2018 to 2026. Increase in prevalence and incidence of diabetic disorders, rise in geriatric population, improved health care as well as health care infrastructure, introduction of combination therapies, and surge in the number of awareness programs are likely to drive the global glaucoma therapeutics market during the forecast period."" The reports continued saying that: "" North America to Remain Leading Revenue Contributor to Global Glaucoma Treatment Market… Incidences of glaucoma in North American countries are rising significantly, with the surge in older population in the region, thereby creating high demand for glaucoma drugs…",BHC,en,Benzinga
2019-05-06 15:31:00-05:00,"Why Bausch Health Companies, Aquantia, and Athenex Jumped Today","Despite pressure on the broader market, these stocks bucked the downtrend.",BHC,en,The Motley Fool
2019-05-06 15:21:55-05:00,Bausch Health Companies Inc. (BHC) Q1 2019 Earnings Call Transcript,"BHC earnings call for the period ending March 31, 2019.",BHC,en,The Motley Fool
2019-05-06 14:49:07-05:00,Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q1 2019 Results - Earnings Call Transcript,"Bausch Health Companies Inc. (NYSE:BHC) Q1 2019 Results Conference Call May 06, 2019 09:00 AM ET Company Participants Arthur Shannon - SVP, Head IR and Global C",BHC,en,Seeking Alpha
2019-05-06 13:00:00-05:00,Bausch Health Companies Posts Strongest Organic Growth in 3 Years,Rising sales in its eye-care segment propelled the drugmaker to its best quarter since 2015.,BHC,en,The Motley Fool
2019-05-06 10:39:00-05:00,Shares of Bausch up 7% after company gives rosier full-year guidance,"Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, raised its full-year outlook on Monday, after reporting first-quarter revenue that…",BHC,en,MarketWatch
2019-05-06 09:00:25-05:00,Bausch Health Companies Inc. 2019 Q1 - Results - Earnings Call Slides,No summary available.,BHC,en,Seeking Alpha
2019-05-06 06:34:00-05:00,Shares of Bausch Health gain 2.4% after company raises full-year guidance,"Shares of Bausch Health Companies Inc. , formerly Valeant Pharmaceuticals International Inc., rose 2.4% in premarket trade Monday after the company reported…",BHC,en,MarketWatch
2019-05-06 06:02:51-05:00,Bausch Health Companies misses on revenue,No summary available.,BHC,en,Seeking Alpha
2019-05-05 16:30:02-05:00,Bausch Health Companies Q1 Earnings Preview,No summary available.,BHC,en,Seeking Alpha
2019-04-25 13:59:42-05:00,Bausch Health Trades Higher On FDA Approval Of Psoriasis Treatment,"Bausch Health Companies Inc (NYSE: BHC ) shares were on the rise Thursday after the company announced federal regulators have approved its new psoriasis lotion. Bausch announced that it received FDA approval for Duobrii, a topical treatment for plaque psoriasis. Trading was halted for a time on Thursday after the afternoon announcement. The new treatment is expected to be a major revenue … Full story available on Benzinga.com",BHC,en,Benzinga
2019-04-25 13:10:34-05:00,UPDATE 1-Bausch Health's lotion for plaque psoriasis wins FDA approval,"The U.S. Food and Drug Administration on Thursday approved Bausch Health Companies Inc's topical plaque psoriasis treatment, which is expected to be a key revenue driver for the company.",BHC,en,Reuters
2019-04-25 12:35:00-05:00,Bausch Health's stock shoots up after NDA for psoriasis treatment gets FDA OK,"Shares of Bausch Health Companies Inc. shot up 3.6% in afternoon trade Thursday, after the company said its new drug application (NDA) for Duobrii for the…",BHC,en,MarketWatch
2019-04-25 12:24:27-05:00,FDA OKs Bausch Health's DUOBRII,"The FDA approves Bausch Health Companies' ([[BHC]] +0.7%) DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.45% to the topical treatment of p",BHC,en,Seeking Alpha
2019-04-25 07:00:32-05:00,Bausch Health in-licenses autoimmune candidate from Mitsubishi Tanabe,Bausch Health Companies (BHC) unit Salix Pharmaceuticals announces that its affiliate has in-licensed an autoimmune disorder candidate called MT-1303 (amis,BHC,en,Seeking Alpha
2019-04-01 06:45:22-05:00,Bausch Health in-licenses fatty liver disease candidate,Bausch Health Companies (BHC) unit Salix Pharmaceuticals has in-licensed an investigational compound from UCLA that targets pituitary adenylate cyclase rec,BHC,en,Seeking Alpha
2019-03-18 05:35:00-05:00,Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within Reach' (NYSE:BHC),"Bausch Health Companies Inc’s (NYSE: BHC) growth drivers will become “more tangible” in 2019, and shares could appreciate as the company …",BHC,en,Benzinga
2019-02-25 07:21:02-05:00,FDA OKs new formulation of Bausch Health's Lotemax,The FDA has approved Bausch Health Companies (BHC) unit Bausch + Lomb's LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postop,BHC,en,Seeking Alpha
2019-02-20 10:00:14-05:00,Bausch Health Companies Inc. 2018 Q4 - Results - Earnings Call Slides,No summary available.,BHC,en,Seeking Alpha
